Journal of Jilin University(Medicine Edition) ›› 2023, Vol. 49 ›› Issue (3): 816-822.doi: 10.13481/j.1671-587X.20230335
• Review • Previous Articles
Received:2022-06-06
Online:2023-05-28
Published:2023-06-28
| 1 | DEL-POZO-LÉRIDA S, SALVADOR C, MARTÍNEZ-SOLER F, et al. Preservation of fertility in patients with cancer (Review)[J]. Oncol Rep, 2019, 41(5): 2607-2614. |
| 2 | 中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 490-500. |
| 3 | DI TUCCI C, CASORELLI A, MORROCCHI E, et al. Fertility management for malignant ovarian germ cell tumors patients[J]. Crit Rev Oncol Hematol, 2017, 120: 34-42. |
| 4 | TAMAUCHI S, KAJIYAMA H, YOSHIHARA M, et al. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study[J]. Am J Obstet Gynecol, 2018, 219(4): 385. |
| 5 | ZHANG N, CHEN R F, HUA K Q,et al. A retrospective study of reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors and sex cord-stromal tumors[J].J Ovarian Res,2017,10(1): 52. |
| 6 | VAN DORP W, HAUPT R, ANDERSON R A, et al. Reproductive function and outcomes in female survivors of childhood, adolescent, and young adult cancer: a review[J]. J Clin Oncol, 2018, 36(21): 2169-2180. |
| 7 | 中国医师协会妇产科医师分会妇科肿瘤学组. 卵巢恶性肿瘤多学科团队协作诊治的中国专家共识[J]. 中华妇产科杂志, 2021, 56(12): 825-830. |
| 8 | DE L M R T, PAUTIER P, REY A, et al. Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases[J]. Eur J Cancer, 2011, 47(2): 175-182. |
| 9 | ZHANG L, CHEN Y, WANG K.Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis[J]. Curr Probl Cancer, 2019, 43(2): 135-144. |
| 10 | CHOI M C, CHUNG Y S, LEE J W,et al. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R)[J]. Eur J Cancer, 2020, 133: 56-65. |
| 11 | MIKUŠ M, BENCO N, MATAK L, et al. Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center[J]. Arch Gynecol Obstet, 2020, 301(5): 1227-1233. |
| 12 | HU T, FANG Y, SUN Q, et al. Clinical management of malignant ovarian germ cell tumors: a 26-year experience in a tertiary care institution[J]. Surg Oncol, 2019, 31: 8-13. |
| 13 | CEPPI L, GALLI F, LAMANNA M, et al. Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms[J]. Gynecol Oncol, 2019, 152(2): 346-352. |
| 14 | 韦任姬, 李 力, 张洁清, 等. 影响卵巢恶性生殖细胞肿瘤保留生育功能手术患者预后的因素分析[J]. 肿瘤防治研究, 2014, 41(9): 962-966. |
| 15 | 刘 倩, 丁西来, 杨佳欣, 等. 卵巢恶性生殖细胞肿瘤手术治疗方式及疗效的多中心临床研究[J]. 中华妇产科杂志, 2013, 48(3): 188-192. |
| 16 | VASTA F M, DELLINO M, BERGAMINI A, et al. Reproductive outcomes and fertility preservation strategies in women with malignant ovarian germ cell tumors after fertility sparing surgery[J]. Biomedicines, 2020, 8(12): 554. |
| 17 | RAY-COQUARD I, MORICE P, LORUSSO D,et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(): iv1-iv18. |
| 18 | LUH L C P N, NYOMAN B M I, AAG P W, et al. Ovarian cancer immature teratoma type in pregnancy: management and feto-maternal outcomes[J]. Open Access Maced J Med Sci, 2019, 7(6): 1016-1020. |
| 19 | KIM H A, CHOI J, PARK C S, et al. Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery[J]. Endocr Connect, 2018, 7(8): 949-956. |
| 20 | DELLINO M, SILVESTRIS E, LOIZZI V, et al. Germinal ovarian tumors in reproductive age women: fertility-sparing and outcome[J]. Medicine (Baltimore), 2020, 99(39): e22146. |
| 21 | NEWTON C, MURALI K, AHMAD A, et al. A multicentre retrospective cohort study of ovarian germ cell tumours: evidence for chemotherapy de-escalation and alignment of paediatric and adult practice[J]. Eur J Cancer, 2019, 113: 19-27. |
| 22 | APPIAH L C. Fertility preservation for adolescents receiving cancer therapies[J]. Clin Obstet Gynecol, 2020, 63(3): 574-587. |
| 23 | TURKMEN O, KARALOK A, BASARAN D, et al. Fertility-sparing surgery should be the standard treatment in patients with malignant ovarian germ cell tumors[J]. J Adolesc Young Adult Oncol, 2017, 6(2): 270-276. |
| 24 | MORRISON A, NASIOUDIS D.Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: a systematic review of the literature[J]. Gynecol Oncol, 2020, 158(2): 476-483. |
| 25 | ZEMLICKIS D, LISHNER M, DEGENDORFER P, et al. Fetal outcome after in utero exposure to cancer chemotherapy[J]. Arch Intern Med, 1992, 152(3): 573-576. |
| 26 | BLUMENFELD Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya,oocytes, or ovaries[J].Oncologist,2007,12(9): 1044-1054. |
| 27 | CHEN Y Y, LUO Y, HAN C, et al. Ovarian dysgerminoma in pregnancy: a case report and literature review[J]. Cancer Biol Ther, 2018, 19(8): 649-658. |
| 28 | ELBRASHY A A, KAMAL A, FAHIM M I. Methods of treatment and outcome for ovarian germ cell tumors[J]. Indian J Surg Oncol, 2019, 10(4): 640-642. |
| 29 | SKÖLD C, BJØRGE T, EKBOM A, et al. Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study[J]. Br J Cancer, 2020, 123(1): 161-166. |
| 30 | KORENAGA T R K, TEWARI K S. Gynecologic cancer in pregnancy[J]. Gynecol Oncol, 2020, 157(3): 799-809. |
| 31 | BAKRI Y N, EZZAT A, AKHTAR, et al. Malignant germ cell tumors of the ovary. Pregnancy considerations[J]. Eur J Obstet Gynecol Reprod Biol, 2000, 90(1): 87-91. |
| 32 | FROYMAN W, LANDOLFO C, DE C B, et al. Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study[J].Lancet Oncol, 2019, 20(3): 448-458. |
| 33 | COCHRANE E, FROST K, DINOBILE C, et al. Immature teratoma diagnosed and treated during pregnancy and later complicated by growing teratoma syndrome: a case review with clinical considerations[J]. Gynecol Oncol Rep, 2020, 32: 100566. |
| 34 | AMANT F, BERVEILLER P, BOERE I A, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting[J]. Ann Oncol, 2019, 30(10): 1601-1612. |
| 35 | SHIGEMI D, ASO S, MATSUI H, et al. Safety of laparoscopic surgery for benign diseases during pregnancy: a nationwide retrospective cohort study[J]. J Minim Invasive Gynecol, 2019, 26(3): 501-506. |
| 36 | YE P P, ZHAO N, SHU J, et al. Laparoscopy versus open surgery for adnexal masses in pregnancy: a meta-analytic review[J]. Arch Gynecol Obstet,2019,299(3): 625-634. |
| 37 | YOUSSEF R, AHMED G S, ALHYASSAT S, et al. Ovarian dysgerminoma in pregnant women with viable fetus: a rare case report[J]. Case Rep Oncol, 2021, 14(1): 141-146. |
| 38 | HJORTEBJERG R. IGFBP-4 and PAPP-a in normal physiology and disease[J]. Growth Horm IGF Res, 2018, 41: 7-22. |
| 39 | ZONG X, YANG J X, ZHANG Y, et al. Clinicopathological characteristics and treatment outcomes of pregnancy complicated by malignant ovarian germ cell tumors[J]. Cancer Manag Res, 2020, 12: 1347-1354. |
| 40 | LUH L C P N, MAHENDRA I N B, SUWIYOGA K, et al. Management comprehensive multidisciplinary of malignant ovarian germ cell tumors and feto-maternal outcome: a case series report and literature review[J]. Open Access Maced J Med Sci, 2019, 7(7): 1174-1179. |
| 41 | DE HAAN J, VERHEECKE M, VAN C K, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients[J]. Lancet Oncol, 2018, 19(3): 337-346. |
| 42 | SON W Y, HENDERSON S, COHEN Y, et al. Immature oocyte for fertility preservation[J]. Front Endocrinol (Lausanne), 2019, 10: 464. |
| 43 | FISCH B, ABIR R. Female fertility preservation: past, present and future[J]. Reproduction, 2018, 156(1): F11-F27. |
| 44 | DOLMANS M M, MANAVELLA D D. Recent advances in fertility preservation[J]. J Obstet Gynaecol Res, 2019, 45(2): 266-279. |
| 45 | DOLMANS M M, DONNEZ J. Fertility preservation in women for medical and social reasons: Oocytes vs ovarian tissue[J]. Best Pract Res Clin Obstet Gynaecol, 2021, 70: 63-80. |
| 46 | ROUSSET-JABLONSKI C, SELLE F, ADDA-HERZOG E, et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers[J]. Eur J Cancer, 2019, 116: 35-44. |
| 47 | MASCIANGELO R, BOSISIO C, DONNEZ J, et al. Safety of ovarian tissue transplantation in patients with borderline ovarian tumors[J]. Hum Reprod, 2018, 33(2): 212-219. |
| 48 | HUSSEIN R S, KHAN Z, ZHAO Y L. Fertility preservation in women: indications and options for therapy[J]. Mayo Clin Proc, 2020, 95(4): 770-783. |
| 49 | 王秋曼, 赵 烨, 姚丽婷, 等. 接受放化疗年轻女性恶性肿瘤患者的生育能力保存[J]. 国际生殖健康/计划生育杂志, 2019, 38(1): 71-74. |
| 50 | WANG S S Y, LOONG H, CHUNG J P W, et al. Preservation of fertility in premenopausal patients with breast cancer[J]. Hong Kong Med J, 2020, 26(3): 216-226. |
| 51 | JOHANSEN G, DAHM-KÄHLER P, STAF C, et al. Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study[J]. Gynecol Oncol, 2019, 155(2): 287-293. |
| 52 | WEISS A, CHAVEZ-MACGREGOR M, LICHTENSZTAJN D Y, et al. Validation study of the American joint committee on cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer[J]. JAMA Oncol, 2018, 4(2): 203-209. |
| 53 | LAMBERTINI M, CINQUINI M, MOSCHETTI I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology[J]. Eur J Cancer, 2017, 71: 25-33. |
| 54 | 丁海遐, 李 文. 女性生育力保存国际指南解读[J]. 实用妇产科杂志, 2020, 36(5): 354-357. |
| 55 | CHO E, KIM Y Y, NOH K, et al. A new possibility in fertility preservation: the artificial ovary[J]. J Tissue Eng Regen Med, 2019, 13(8): 1294-1315. |
| 56 | LARONDA M M, RUTZ A L, XIAO S, et al. A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice[J]. Nat Commun, 2017, 8: 15261. |
| No related articles found! |
|
||